Immunovant Files 8-K

Ticker: IMVT · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1764013

Sentiment: neutral

Topics: reporting, sec-filing

Related Tickers: IMVT

TL;DR

IMVT filed a routine 8-K, no major news.

AI Summary

Immunovant, Inc. filed an 8-K on September 3, 2025, reporting on other events and financial statements. The filing does not contain specific material events or financial figures beyond standard reporting requirements.

Why It Matters

This filing indicates Immunovant is meeting its regular reporting obligations with the SEC, providing transparency to investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting purposes and does not disclose any new material risks or events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Immunovant, Inc.?

The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of September 3, 2025.

When was Immunovant, Inc. incorporated or organized?

Immunovant, Inc. was incorporated or organized in Delaware.

What is the principal executive office address for Immunovant, Inc.?

The principal executive office address is 320 West 37th Street, New York, NY 10018.

What was the former name of Immunovant, Inc.?

The former name of Immunovant, Inc. was Health Sciences Acquisitions Corp.

What is the SIC code for Immunovant, Inc.?

The Standard Industrial Classification (SIC) code for Immunovant, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 638 words · 3 min read · ~2 pages · Grade level 9.2 · Accepted 2025-09-03 13:09:06

Key Financial Figures

Filing Documents

01. Regulation FD Disclo sure

Item 7.01. Regulation FD Disclo sure. On September 3, 2025, Immunovant, Inc. (the "Company") issued a press release providing an update on its Graves' Disease ("GD") development program. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01. Other Events

Item 8.01. Other Events. On September 3, 2025, the Company posted a presentation regarding the update on its GD proof-of-concept study on the "Presentations" page of its investor relations website at https://www.immunovant.com/investors and will host a conference call and webcast to discuss the remission data from the GD trial at 4:30 p.m. E.D.T. A copy of the presentation to be used by the Company during the conference call is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The contents of the Company's website referenced in this Current Report on Form 8-K are not incorporated into this Current Report on Form 8-K.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated September 3, 2025. 99.2 Presentation, dated September 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOVANT, INC. By: /s/ Tiago Girao Tiago Girao Chief Financial Officer Date: September 3, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing